Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645281 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 896
- Enrollment target
NCT00645281: Completed Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00645281 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 896 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00645281, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 896 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.
Interventions
- DRUG tolterodine extended release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 896 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-01 |
| Phase | Phase 4 |
What the finished NCT00645281 record still lists
NCT00645281 is an interventional study that assigns participants to a tested intervention. The registered 896 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% higher).
The record links to 0 conditions, and to 1 intervention - of which tolterodine extended release is the first listed.
NCT00645281 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00645281 about?
NCT00645281 is a clinical study titled "A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.". The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.
What is the current status of trial NCT00645281?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 896 participants. The study started on 2004-03. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00645281?
The interventions under investigation include: tolterodine extended release (DRUG).
Who is sponsoring clinical trial NCT00645281?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00645281's enrollment target sits among peer trials
896 86th of 2000 higher than 1,915 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia